Amgen’s European EPO Sales Unaffected By Biosimilars, Company Says
Executive Summary
The European launch of biosimilar erythropoietin products has failed to impact European sales of Amgen's EPO products, EVP Worldwide Sales and Marketing George Morrow said during the company's third quarter earnings call Oct. 24
You may also be interested in...
Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel
While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs
Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel
While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs
Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability
Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.